ABL1 and acute lymphoblastic leukemia: In contrast to the BCR::ABL1 rearrangement in Ph-positive disease, which can be targeted by contemporary tyrosine kinase inhibitors (TKIs), the absence of a well-defined molecular target in Ph-negative disease has led to intense efforts to develop immunotherapies for this subset of B-ALL.